featured
Isatuximab, Carfilzomib, and Dexamethasone in Relapsed Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Isatuximab, Carfilzomib, and Dexamethasone in Relapsed Multiple Myeloma (IKEMA): A Multicentre, Open-Label, Randomised Phase 3 Trial
Lancet 2021 Jun 04;[EPub Ahead of Print], P Moreau, MA Dimopoulos, J Mikhael, K Yong, M Capra, T Facon, R Hajek, I Špička, R Baker, K Kim, G Martinez, CK Min, L Pour, X Leleu, A Oriol, Y Koh, K Suzuki, ML Risse, G Asset, S Macé, T MartinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.